Publications by authors named "Hein P J Visser"
Article Synopsis
- The GAIA/CLL13 trial found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib combinations led to better undetectable measurable residual disease (MRD) rates and longer progression-free survival compared to traditional chemoimmunotherapy for untreated chronic lymphocytic leukaemia (CLL) patients.
- The trial was a phase 3 study involving 159 sites across Europe and the Middle East, enrolling patients aged 18 and older with specific health criteria and assigning them to different treatment groups, including standard chemoimmunotherapy and various venetoclax-based combinations.
- All treatment regimens were administered in cycles, with detailed protocols for each group, specifically focusing on
Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23). Because both CLL as well as immunosuppressive treatment have been identified as major determinants of immunogenicity, we aimed to assess the vaccination schedule in untreated and treated CLL patients.
View Article and Find Full Text PDFChronic lymphocytic leukemia (CLL)-related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to geriatric characteristics and aim for an improvement in health-related quality of life (HRQoL) as a primary treatment goal. In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67).
View Article and Find Full Text PDFArticle Synopsis
- - The management of chronic lymphocytic leukemia (CLL) is evolving due to new therapies and advancements in treatment options, prompting a revision of Dutch guidelines.
- - The updated guidelines from the HOVON CLL working group emphasize evidence from clinical trials, focusing on factors like efficacy, toxicity, treatment duration, and intensity.
- - The article offers recommendations on diagnosing CLL, treatment strategies for both newly diagnosed and relapsed patients, and supportive care for complications related to the disease, tailored to current treatment availability in the Netherlands.
Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status.
Methods: We conducted an open-label, randomised, parallel-group, phase 2 trial (HOVON 139/GiVe) at 25 hospitals in the Netherlands.
Introduction: In recent years, considerable progress has been made in the treatment of patients with chronic lymphocytic leukemia (CLL), and new potent drugs have become available. Therefore, the CLL working party revised the Dutch guidelines. Not only efficacy but also quality of life and socio-economic impact were taken into account in the formulation of treatment recommendations.
View Article and Find Full Text PDF